ReviewFrontiers in immunology2026
Macrophage polarization in gynecologic malignancies: key signaling pathways and clinical perspectives.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gynecological malignancies represent a significant global health burden for women worldwide. Tumor-associated macrophages (TAMs), as a critical component of the immune system, play a pivotal role within the tumor microenvironment (TME). Modulating signaling pathways in the TME can promote the polarization of TAMs toward the M1 phenotype, thereby enhancing anti-tumor effects and suppressing tumor growth and metastasis. The rapid advancement of nano-drug delivery systems (NDDSs) has expanded the potential for clinical translation of immunotherapies targeting TAMs. Our review provides an overview of the latest research progress on TAMs polarization-related signaling pathways and the use of NDDSs for targeted TAMs therapy in gynecological malignancies. Concurrently, the challenges encountered during the clinical translation of these therapeutic measures and future directions are discussed, aiming to provide novel insights for the immunotherapy of gynecological malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.